Pfizer, BioNTech sign $1.9bn deal for additional doses of BNT162b2 with US
By 31 July 2021, the US government is expected to get 200 million doses of the BNT162b2 Covid-19…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Dec 20
By 31 July 2021, the US government is expected to get 200 million doses of the BNT162b2 Covid-19…
23 Dec 20
Treatment using tezepelumab did not meet the primary endpoint of statistically significant reduction in the daily OCS dose,…
22 Dec 20
The transaction includes Agios' marketed medicine Tibsovo and its oncology pipeline of Phase 3 and early-stage assets
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Dec 20
The company intends to deliver around 20 million doses to the US government by the end of December…
18 Dec 20
The FDA approval is based on the positive results of the BLISS-LN study, and the prevalent unmet medical…
18 Dec 20
Riabni is a cytolytic antibody that works similar to Rituxan, with no clinically meaningful differences in safety or…
17 Dec 20
The new cGMP facility in Carlsbad, California would expand the commercialisation of plasmid-based medicines and vaccines
PharmaceuticalsProtein and Peptide Synthesis and Manufacturing
17 Dec 20
The Swiss pharmaceutical firm also secured Rare Pediatric Disease Designation for the treatment of C3 glomerulopathy (C3G)
16 Dec 20
The acquisition will help Lilly establish a gene therapy programme, backed by Prevail's portfolio of neuroscience assets
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Dec 20
The US FDA approval is based on data from the ENSEMBLE PLUS study, in which two-hour Ocrevus infusion…